he role of immunotherapy for the adjuvant treatment of BRAF-mutant melanoma
The introduction of anti-PD-1 drugs as an adjuvant treatment for high risk melanoma has radically changed the everyday clinical practice, with an impact on the reduction of the risk of relapse close to 50%, as observed in phase 3 clinical trials. In patients whose tumors harbor a BRAF mutation, the combination of BRAF plus MEK inhibitors is also a valuable option, with outcomes in terms of 3-year RFS similar to those observed with anti-PD-1 immunotherapy. However, numerous questions remain unanswered, particularly which is the best treatment in BRAF-mutant patients. The aim of this review was to analyze the results of randomized phase 3 clinical trials, with a focus on some hot topics and discussing the role of immunotherapy for the adjuvant treatment of BRAF-mutant melanoma.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:111 |
|---|---|
| Enthalten in: |
Recenti progressi in medicina - 111(2020), 12 vom: 01. Dez., Seite 39e-47e |
| Sprache: |
Italienisch |
|---|
| Weiterer Titel: |
Il ruolo dell’immunoterapia adiuvante nei pazienti con melanoma BRAF-mutato |
|---|
| Beteiligte Personen: |
Spagnolo, Francesco [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
BRAF protein, human |
|---|
| Anmerkungen: |
Date Completed 13.04.2022 Date Revised 13.04.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1701/3509.34975 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM31926484X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM31926484X | ||
| 003 | DE-627 | ||
| 005 | 20231225171103.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||ita c | ||
| 024 | 7 | |a 10.1701/3509.34975 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1064.xml |
| 035 | |a (DE-627)NLM31926484X | ||
| 035 | |a (NLM)33362181 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ita | ||
| 100 | 1 | |a Spagnolo, Francesco |e verfasserin |4 aut | |
| 245 | 1 | 3 | |a he role of immunotherapy for the adjuvant treatment of BRAF-mutant melanoma |
| 246 | 3 | 3 | |a Il ruolo dell’immunoterapia adiuvante nei pazienti con melanoma BRAF-mutato |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.04.2022 | ||
| 500 | |a Date Revised 13.04.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The introduction of anti-PD-1 drugs as an adjuvant treatment for high risk melanoma has radically changed the everyday clinical practice, with an impact on the reduction of the risk of relapse close to 50%, as observed in phase 3 clinical trials. In patients whose tumors harbor a BRAF mutation, the combination of BRAF plus MEK inhibitors is also a valuable option, with outcomes in terms of 3-year RFS similar to those observed with anti-PD-1 immunotherapy. However, numerous questions remain unanswered, particularly which is the best treatment in BRAF-mutant patients. The aim of this review was to analyze the results of randomized phase 3 clinical trials, with a focus on some hot topics and discussing the role of immunotherapy for the adjuvant treatment of BRAF-mutant melanoma | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Immunologic Factors |2 NLM | |
| 650 | 7 | |a Protein Kinase Inhibitors |2 NLM | |
| 650 | 7 | |a BRAF protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 650 | 7 | |a Proto-Oncogene Proteins B-raf |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Recenti progressi in medicina |d 1948 |g 111(2020), 12 vom: 01. Dez., Seite 39e-47e |w (DE-627)NLM000023124 |x 2038-1840 |7 nnns |
| 773 | 1 | 8 | |g volume:111 |g year:2020 |g number:12 |g day:01 |g month:12 |g pages:39e-47e |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1701/3509.34975 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 111 |j 2020 |e 12 |b 01 |c 12 |h 39e-47e | ||